Donald Goff
Donald Goff
NYU School of Medicine
Verified email at
Cited by
Cited by
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia …
JP McEvoy, JM Meyer, DC Goff, HA Nasrallah, SM Davis, L Sullivan, ...
Schizophrenia research 80 (1), 19-32, 2005
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia
DC Goff, JT Coyle
American Journal of Psychiatry 158 (9), 1367-1377, 2001
Regionally localized thinning of the cerebral cortex in schizophrenia
GR Kuperberg, MR Broome, PK McGuire, AS David, M Eddy, F Ozawa, ...
Archives of general psychiatry 60 (9), 878-888, 2003
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study
DC Henderson, E Cagliero, C Gray, RA Nasrallah, DL Hayden, ...
American Journal of Psychiatry 157 (6), 975-981, 2000
Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects.
DC Goff, DC Henderson, E Amico
The American journal of psychiatry 149 (9), 1189-1194, 1992
Impaired recruitment of the hippocampus during conscious recollection in schizophrenia
S Heckers, S Rauch, D Goff, C Savage, D Schacter, A Fischman, N Alpert
Nature neuroscience 1 (4), 318-323, 1998
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline
HA Nasrallah, JM Meyer, DC Goff, JP McEvoy, SM Davis, TS Stroup, ...
Schizophrenia research 86 (1-3), 15-22, 2006
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
DC Goff, LM Sullivan, JP McEvoy, JM Meyer, HA Nasrallah, GL Daumit, ...
Schizophrenia research 80 (1), 45-53, 2005
Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance
DS Manoach, RL Gollub, ES Benson, MM Searl, DC Goff, E Halpern, ...
Biological psychiatry 48 (2), 99-109, 2000
Cognitive therapy for psychosis in schizophrenia: an effect size analysis
RA Gould, KT Mueser, E Bolton, V Mays, D Goff
Schizophrenia research 48 (2-3), 335-342, 2001
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia
RW Buchanan, M Davis, D Goff, MF Green, RSE Keefe, AC Leon, ...
Schizophrenia bulletin 31 (1), 5-19, 2005
Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia
JT Coyle, G Tsai, D Goff
Annals of the New York Academy of Sciences 1003 (1), 318-327, 2003
A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia
DC Goff, G Tsai, J Levitt, E Amico, D Manoach, DA Schoenfeld, ...
Archives of general psychiatry 56 (1), 21-27, 1999
Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI
DS Manoach, DZ Press, V Thangaraj, MM Searl, DC Goff, E Halpern, ...
Biological psychiatry 45 (9), 1128-1137, 1999
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis
DC Henderson, E Cagliero, PM Copeland, CP Borba, AE Evins, ...
Archives of general psychiatry 62 (1), 19-28, 2005
Reduced sleep spindles and spindle coherence in schizophrenia: mechanisms of impaired memory consolidation?
EJ Wamsley, MA Tucker, AK Shinn, KE Ono, SK McKinley, AV Ely, ...
Biological psychiatry 71 (2), 154-161, 2012
Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists.
DC Goff, C Cather, AE Evins, DC Henderson, O Freudenreich, ...
Journal of Clinical Psychiatry 66 (2), 183-194, 2005
Association of psychiatric disorders with mortality among patients with COVID-19
K Nemani, C Li, M Olfson, EM Blessing, N Razavian, J Chen, E Petkova, ...
JAMA psychiatry 78 (4), 380-386, 2021
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1
JM Meyer, VG Davis, DC Goff, JP McEvoy, HA Nasrallah, SM Davis, ...
Schizophrenia research 101 (1-3), 273-286, 2008
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.
DC Goff, G Tsai, DS Manoach, JT Coyle
The American journal of psychiatry 152 (8), 1213-1215, 1995
The system can't perform the operation now. Try again later.
Articles 1–20